{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:11:27Z","timestamp":1792145487267,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS118197"],"award-info":[{"award-number":["R01NS118197"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01HL152101"],"award-info":[{"award-number":["R01HL152101"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["LI21G0"],"award-info":[{"award-number":["LI21G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["REZNI23Y3"],"award-info":[{"award-number":["REZNI23Y3"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH135862"],"award-info":[{"award-number":["R01MH135862"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Psychologica"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.actpsy.2026.106210","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:47:43Z","timestamp":1768279663000},"page":"106210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Divergent neurobehavioral effects of CFTR modulators elexacaftor and ivacaftor in mice"],"prefix":"10.1016","volume":"263","author":[{"given":"Qian","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Fagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah R.","family":"Reznikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actpsy.2026.106210_bb0005","series-title":"Australian public assessment report for tezacaftor\/ivacaftor and ivacaftor","year":"2019"},{"key":"10.1016\/j.actpsy.2026.106210_bb0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","article-title":"Intraperitoneal route of drug administration: Should it be used in experimental animal studies?","volume":"37","author":"Al Shoyaib","year":"2019","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.actpsy.2026.106210_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20110","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis","volume":"9","author":"Allgood","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.actpsy.2026.106210_bb0020","first-page":"1","article-title":"Anxiety and depression in cystic fibrosis","volume":"106","author":"Baiardini","year":"2015","journal-title":"Minerva Medica"},{"key":"10.1016\/j.actpsy.2026.106210_bb0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0304-3940(84)90532-9","article-title":"GABA actions on the excitability of cultured CNS neurons","volume":"47","author":"Barker","year":"1984","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.actpsy.2026.106210_bb0030","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/ppul.26412","article-title":"Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"58","author":"Baroud","year":"2023","journal-title":"Pediatric Pulmonology"},{"key":"10.1016\/j.actpsy.2026.106210_bb0035","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jcf.2024.11.006","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and mental health: A workshop report from the Cystic Fibrosis Foundation\u2019s Prioritizing Research in Mental Health working group","volume":"24","author":"Bathgate","year":"2025","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.actpsy.2026.106210_bb0040","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic effects of elexacaftor-tezacaftor-ivacaftor in adults with cystic fibrosis and advanced lung disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1016\/j.actpsy.2026.106210_bb0045","unstructured":"C. f. D. E. a. R. U. S. F. a. D. Administration. (2012) Pharmacology Review: Application Number 203188Orig1s000. in NDA 203188 (Vertex Pharmaceuticals, Inc., Ivacaftor) ed P. D. Timothy W. Robison, D.A.B.T."},{"key":"10.1016\/j.actpsy.2026.106210_bb0050","author":"C. F. Foundation"},{"key":"10.1016\/j.actpsy.2026.106210_bb0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0166-4328(01)00452-1","article-title":"Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behaviour in inbred mice","volume":"134","author":"Carola","year":"2002","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.actpsy.2026.106210_bb0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0149-7634(01)00011-2","article-title":"A detailed ethological analysis of the mouse open field test: Effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field","volume":"25","author":"Choleris","year":"2001","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.actpsy.2026.106210_bb0065","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jcf.2024.05.004","article-title":"Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS)","volume":"23","author":"Ciobanu","year":"2024","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.actpsy.2026.106210_bb0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5863\/1551-6776-18.1.8","article-title":"Ivacaftor: A novel gene-based therapeutic approach for cystic fibrosis","volume":"18","author":"Condren","year":"2013","journal-title":"Journal of Pediatric Pharmacology and Therapeutics"},{"key":"10.1016\/j.actpsy.2026.106210_bb0075","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.mp.4001457","article-title":"In search of a depressed mouse: Utility of models for studying depression-related behavior in genetically modified mice","volume":"9","author":"Cryan","year":"2004","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.actpsy.2026.106210_bb0080","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40265-016-0611-2","article-title":"Lumacaftor\/ivacaftor: A review in cystic fibrosis","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.actpsy.2026.106210_bb0085","series-title":"Kaftrio: Assessment report (EMA\/385871\/2020 Rev.1; CHMP)","first-page":"178","author":"E. M. Agency","year":"2020"},{"key":"10.1016\/j.actpsy.2026.106210_bb0090","series-title":"The mouse brain in stereotaxic coordinates","author":"Franklin","year":"2012"},{"key":"10.1016\/j.actpsy.2026.106210_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2024.110981","article-title":"Chronic restraint stress induces depression-like behaviors and alterations in the afferent projections of medial prefrontal cortex from multiple brain regions in mice","volume":"213","author":"Ge","year":"2024","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.actpsy.2026.106210_bb0100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0304-3940(84)90514-7","article-title":"Benzodiazepine interactions with GABA receptors","volume":"47","author":"Haefely","year":"1984","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.actpsy.2026.106210_bb0105","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jcf.2008.05.010","article-title":"Quality of life in patients with cystic fibrosis: Association with anxiety and depression","volume":"7","author":"Havermans","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.actpsy.2026.106210_bb0110","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/MCP.0000000000000617","article-title":"Prevention of anxiety and depression in cystic fibrosis","volume":"25","author":"Havermans","year":"2019","journal-title":"Current Opinion in Pulmonary Medicine"},{"key":"10.1016\/j.actpsy.2026.106210_bb0115","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.actpsy.2026.106210_bb0120","first-page":"329","article-title":"A spoonful of sugar helps the medicine go down: A novel technique to improve oral gavage in mice","volume":"49","author":"Hoggatt","year":"2010","journal-title":"Journal of the American Association for Laboratory Animal Science"},{"key":"10.1016\/j.actpsy.2026.106210_bb0125","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s40265-019-01233-7","article-title":"Elexacaftor\/ivacaftor\/tezacaftor: First approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.actpsy.2026.106210_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.actpsy.2026.106210_bb0135","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/FBP.0b013e32834afebe","article-title":"Pharmacological evaluation of the adequacy of marble burying as an animal model of compulsion and\/or anxiety","volume":"22","author":"Jimenez-Gomez","year":"2011","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.actpsy.2026.106210_bb0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jneumeth.2014.06.012","article-title":"Marble burying as a test of the delayed anxiogenic effects of acute immobilisation stress in mice","volume":"233","author":"Kedia","year":"2014","journal-title":"Journal of Neuroscience Methods"},{"key":"10.1016\/j.actpsy.2026.106210_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6503162","article-title":"Coping with the forced swim stressor: Towards understanding an adaptive mechanism","volume":"2016","author":"de Kloet","year":"2016","journal-title":"Neural Plasticity"},{"key":"10.1016\/j.actpsy.2026.106210_bb0150","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02774-2020","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator","volume":"57","author":"Laselva","year":"2021","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.actpsy.2026.106210_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116155","article-title":"Fetal drug exposure after maternally administered CFTR modulators elexacaftor\/tezacaftor\/ivacaftor in a rat model","volume":"171","author":"Li","year":"2024","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.actpsy.2026.106210_bb0160","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1165\/ajrcmb\/8.2.201","article-title":"Cystic fibrosis gene and protein expression during fetal lung development","volume":"8","author":"McGrath","year":"1993","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.actpsy.2026.106210_bb0165","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.actpsy.2026.106210_bb0170","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1097\/00001756-199408150-00035","article-title":"Cystic fibrosis transmembrane conductance regulator protein expression in brain","volume":"5","author":"Mulberg","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.actpsy.2026.106210_bb0175","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1172\/JCI118080","article-title":"Expression and localization of the cystic fibrosis transmembrane conductance regulator mRNA and its protein in rat brain","volume":"96","author":"Mulberg","year":"1995","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.actpsy.2026.106210_bb0180","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0423-19.2020","article-title":"Chemogenetic inhibition of infralimbic prefrontal cortex GABAergic parvalbumin interneurons attenuates the impact of chronic stress in male mice","volume":"7","author":"Nawreen","year":"2020","journal-title":"eNeuro"},{"key":"10.1016\/j.actpsy.2026.106210_bb0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1211\/0022357001773670","article-title":"Oral, intraperitoneal and intravenous pharmacokinetics of deramciclane and its N-desmethyl metabolite in the rat","volume":"52","author":"Nemes","year":"2000","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.actpsy.2026.106210_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1179208","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis","volume":"14","author":"Piehler","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.actpsy.2026.106210_bb0195","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/gbb.12108","article-title":"Localization and behaviors in null mice suggest that ASIC1 and ASIC2 modulate responses to aversive stimuli","volume":"13","author":"Price","year":"2014","journal-title":"Genes, Brain, and Behavior"},{"key":"10.1016\/j.actpsy.2026.106210_bb0200","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jcf.2021.06.005","article-title":"Entry of cystic fibrosis transmembrane conductance potentiator ivacaftor into the developing brain and lung","volume":"20","author":"Qiu","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.actpsy.2026.106210_bb0205","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: Results of The International Depression Epidemiological Study across nine countries","volume":"69","author":"Quittner","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.actpsy.2026.106210_bb0210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.actpsy.2026.106210_bb0215","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.chest.2016.11.009","article-title":"Cystic fibrosis and the nervous system","volume":"151","author":"Reznikov","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.actpsy.2026.106210_bb0220","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1378\/chest.06-2474","article-title":"The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis","volume":"132","author":"Riekert","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.actpsy.2026.106210_bb0225","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ppul.26260","article-title":"A survey assessing the impact of COVID-19 and elexacaftor\/tezacaftor\/ifavacaftor on both physical and mental health in adults with cystic fibrosis","volume":"58","author":"Sakon","year":"2023","journal-title":"Pediatric Pulmonology"},{"key":"10.1016\/j.actpsy.2026.106210_bb0230","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00127-2017","article-title":"The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites","volume":"4","author":"Schneider","year":"2018","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.actpsy.2026.106210_bb0235","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"European Respiratory Review"},{"key":"10.1016\/j.actpsy.2026.106210_bb0240","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nprot.2012.044","article-title":"Using the rat forced swim test to assess antidepressant-like activity in rodents","volume":"7","author":"Slattery","year":"2012","journal-title":"Nature Protocols"},{"key":"10.1016\/j.actpsy.2026.106210_bb0245","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/ppul.22990","article-title":"Depression, illness severity, and healthcare utilization in cystic fibrosis","volume":"49","author":"Snell","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1016\/j.actpsy.2026.106210_bb0250","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.actpsy.2026.106210_bb0255","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.biopsych.2008.02.022","article-title":"Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal","volume":"64","author":"Surget","year":"2008","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.actpsy.2026.106210_bb0260","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.psym.2020.06.021","article-title":"Trikafta and psychopathology in cystic fibrosis: A case report","volume":"61","author":"Tindell","year":"2020","journal-title":"Psychosomatics"},{"key":"10.1016\/j.actpsy.2026.106210_bb0265","first-page":"600","article-title":"Administration of substances to laboratory animals: Routes of administration and factors to consider","volume":"50","author":"Turner","year":"2011","journal-title":"Journal of the American Association for Laboratory Animal Science"},{"key":"10.1016\/j.actpsy.2026.106210_bb0270","series-title":"Multi-discipline review","first-page":"245","author":"U. S. F. a. D. A. C. f. D. E. a. Research","year":"2019"},{"key":"10.1016\/j.actpsy.2026.106210_bb0275","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nprot.2007.44","article-title":"The use of the elevated plus maze as an assay of anxiety-related behavior in rodents","volume":"2","author":"Walf","year":"2007","journal-title":"Nature Protocols"},{"key":"10.1016\/j.actpsy.2026.106210_bb0280","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4187\/respcare.01328","article-title":"Relationship between anxiety, depression, and quality of life in adult patients with cystic fibrosis","volume":"57","author":"Yohannes","year":"2012","journal-title":"Respiratory Care"}],"container-title":["Acta Psychologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001691826000090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001691826000090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:14:16Z","timestamp":1786972456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001691826000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":56,"alternative-id":["S0001691826000090"],"URL":"https:\/\/doi.org\/10.1016\/j.actpsy.2026.106210","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.07.02.662194","asserted-by":"object"}]},"ISSN":["0001-6918"],"issn-type":[{"value":"0001-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Divergent neurobehavioral effects of CFTR modulators elexacaftor and ivacaftor in mice","name":"articletitle","label":"Article Title"},{"value":"Acta Psychologica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actpsy.2026.106210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106210"}}